Canadian Breast Cancer Network urges vigilant monitoring of chemotherapy drugs to promote patient safety.
The Canadian Breast Cancer Network (CBCN) recommends close monitoring of chemotherapy dosages to ensure the safety of chemotherapy treatments for patients.
As nearly 1,200 cancer patients in Ontario and New Brunswick have been affected by diluted treatments of Cyclophosphamide and Gemcitabine, CBCN would like to highlight the importance of vigilant monitoring of chemotherapy preparation and administration, as well as encourage continued adherence to strict quality control guidelines to assure patient safety.
“Patient safety should remain the focus of the system,” said Cathy Ammendolea, Board Chair, Canadian Breast Cancer Network. “It is vital that patients are informed of the impact of the diluted medications on their treatment outcomes and that adequate measures are taken to ensure that these errors don’t occur again.”
CBCN commends the swift action of Cancer Care Ontario and the affected hospitals in removing the affected medications and securing appropriate supplies of the medications for all subsequent treatments. CBCN also encourages close follow-up of this situation and supports the implementation of strong measures to minimize potential sources of error and maximize high quality patient care in the future.
For more information, please contact CBCN at 613-230-3044 or email@example.com.
About the Canadian Breast Cancer Network
The Canadian Breast Cancer Network is the leading survivor-directed, national network of organizations and individuals concerned about breast cancer. The Canadian Breast Cancer Network exists to voice the concerns of breast cancer survivors and promote the best quality of care for all Canadians affected by breast cancer.